Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.

about

Advances in the treatment of HIV/HCV coinfection in adults.Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir.

P2860

Q47291511-210386E1-C368-4418-ACF9-1386C726F6D8 Q48223561-99121EC6-0F11-4C36-BF29-B371829201FF

P2860

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.

Item

http://www.wikidata.org/entity/Q38927209

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Ombitasvir/Paritaprevir/Ritona ...... and Drugs forSubstance Abuse.

@en

type

Item

label

Ombitasvir/Paritaprevir/Ritona ...... and Drugs forSubstance Abuse.

@en

prefLabel

Ombitasvir/Paritaprevir/Ritona ...... and Drugs forSubstance Abuse.

@en

P1476

Ombitasvir/Paritaprevir/Ritona ...... and Drugs forSubstance Abuse.

@en

P2093

Jennifer R King

http://www.w3.org/2001/XMLSchema#string

Rajeev M Menon

http://www.w3.org/2001/XMLSchema#string

P2860

Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy

Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes

Membrane transporters in drug development

Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine

Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans

Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine

Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.

Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.

P304

201-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPDD.327

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28263457

http://www.w3.org/2001/XMLSchema#string

P921

ombitasvir

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.

about

P2860

P2860

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921